Treatment of advanced or metastatic hepatocellular cancer (HCC): Interim analysis of a single-arm phase II study of bevacizumab and RAD001

被引：5
|
作者：
Treiber, G. [1 ]
机构：
[1] Zollemalb Clin, Dept Internal Med, Balingen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4102
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) Preliminary Safety Analysis of a Single-ARM Phase II Study of Bevacizumab and Rad001
    Treiber, Gerhard
    GASTROENTEROLOGY, 2010, 138 (05) : S811 - S811
  • [2] Treatment of advanced or metastatic hepatocellular cancer (HCC) - preliminary safety analysis of a single-arm phase II study of bevacizumab and RAD001
    Treiber, G.
    ONKOLOGIE, 2010, 33 : 8 - 9
  • [3] Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - Clinical Results of a Single-ARM Phase II Study of Bevacizumab and Everolimus
    Treiber, Gerhard
    GASTROENTEROLOGY, 2012, 142 (05) : S922 - S922
  • [4] Treatment of advanced or metastatic hepatocellular cancer (HCC): Final clinical results of a single-arm phase II study of bevacizumab and everolimus
    Treiber, Gerhard
    Wex, Thomas
    Schneider, Guenther
    Roecken, Cristoph
    Dufour, Jean-Francois
    Geisel, Juergen
    Hardikar, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Modified-dose capecitabine plus bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II, single-arm study
    Hsu, C.
    Yang, T.
    Hsu, C.
    Toh, H.
    Epstein, R. J.
    Hsiao, L.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Thalidomide plus tegafur/uracil for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II single-arm study
    Hsu, C.
    Chang, D.
    Lin, Z.
    Lee, K.
    Hsiao, C.
    Shen, Y.
    Cheng, A.
    Hsu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)
    Whorf, R. C.
    Hainsworth, J. D.
    Spigel, D. R.
    Yardley, D. A.
    Burris, H. A., III
    Waterhouse, D. M.
    Vazquez, E. R.
    Greco, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer
    Wolpin, B. M.
    Hezel, A. F.
    Ryan, D. P.
    Abrams, T. A.
    Meyerhardt, J. A.
    Blaszkowsky, L. S.
    Clark, J. W.
    Allen, B.
    Regan, E. M.
    Fuchs, C. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study
    Hao, Chunyi
    Du, Chengyou
    Peng, Baogang
    Zhang, Wu
    Shan, Yunfeng
    Lv, Ang
    Wu, Jianhui
    Shang, Changzhen
    Luo, Xuan
    Wei, Jinxing
    Xiao, Heng
    Qiu, Jianguo
    Hua, Yunpeng
    Shen, Shunli
    Wang, Ting
    Dai, Shengjie
    Chen, Xiang
    Yan, Shican
    Hao, Chunyi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [10] RAMSETE: A single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in Europe.
    Pavel, Marianne E.
    Wiedenmann, Bertram
    Capdevila, Jaume
    Reed, Nicholas
    Valle, Juan W.
    Caglio, Silvia
    May, Christoph
    Comis, Silvia
    Castellana, Ramon
    de Herder, W. W.
    Metzner, Cornelia
    Salazar, Ramon
    Hoersch, Dieter
    Oberg, Kjell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345